INT55256

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1994
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 38
Total Number 38
Disease Relevance 16.12
Pain Relevance 13.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Il6) aging (Il6) extracellular region (Il6)
Anatomy Link Frequency
adrenal cortex 4
macrophage 2
smooth muscle 2
fibroblasts 2
Nociceptors 2
Il6 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammation 304 100.00 Very High Very High Very High
Inflammatory mediators 7 100.00 Very High Very High Very High
cytokine 122 99.98 Very High Very High Very High
agonist 118 99.98 Very High Very High Very High
gABA 47 99.98 Very High Very High Very High
dexamethasone 29 99.90 Very High Very High Very High
corticosteroid 8 99.84 Very High Very High Very High
COX2 15 99.76 Very High Very High Very High
Inflammatory response 90 99.72 Very High Very High Very High
antagonist 88 99.70 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 412 100.00 Very High Very High Very High
Cancer 70 100.00 Very High Very High Very High
Necrosis 12 100.00 Very High Very High Very High
Cv General 4 Under Development 4 99.72 Very High Very High Very High
Glioma 7 98.76 Very High Very High Very High
Pain 18 97.76 Very High Very High Very High
Post Operative Pain 2 96.16 Very High Very High Very High
Arthritis 16 94.60 High High
Neuroma 3 94.32 High High
Myxoma 2 94.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: Stimulation of control specimens increased IL-6 secretion (median increase, 147%; p < 0.003), which was prevented by CsA.
Negative_regulation (prevented) of Localization (secretion) of IL-6
1) Confidence 0.58 Published 1994 Journal Scand. J. Gastroenterol. Section Body Doc Link 7973432 Disease Relevance 0.16 Pain Relevance 0
Both CGRP antagonists significantly reduced IL-6 release from injured nerve explants.
Negative_regulation (reduced) of Localization (release) of IL-6 in nerve associated with antagonist and calcitonin gene-related peptide
2) Confidence 0.58 Published 2006 Journal J. Neurochem. Section Abstract Doc Link 16805807 Disease Relevance 0.82 Pain Relevance 1.33
LPS-induced IL-6 release was partially inhibited by BW 4AC, a 5-lipoxygenase inhibitor.
Negative_regulation (inhibited) of Localization (release) of IL-6
3) Confidence 0.57 Published 1998 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 9784426 Disease Relevance 0.07 Pain Relevance 0.25
We found that L-NO-arginine, an inhibitor of nitric oxide synthase, concentration-dependently reduced LPS-induced IL-6 release in astrocytes.
Neg (NO) Negative_regulation (reduced) of Localization (release) of IL-6 in astrocytes
4) Confidence 0.57 Published 1998 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 9784426 Disease Relevance 0.07 Pain Relevance 0.32
These results indicate that the effects of naproxen in vivo were due, at least in part, to direct suppression of IL-6 secretion from the tumour.
Negative_regulation (suppression) of Localization (secretion) of IL-6 associated with cancer
5) Confidence 0.57 Published 2001 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 11298095 Disease Relevance 1.12 Pain Relevance 0.32
Cultured tumour cells showed IL-6 protein synthesis, and nonsteroidal anti-inflammatory drugs such as naproxen and indomethacin directly inhibited IL-6 release.
Negative_regulation (inhibited) of Localization (release) of IL-6 associated with inflammation, cancer and cinod
6) Confidence 0.57 Published 2001 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 11298095 Disease Relevance 1.08 Pain Relevance 0.34
Flurbiprofen may have reduced interleukin-6 secretion by the tumor, leading to a delayed diagnosis.
Negative_regulation (reduced) of Localization (secretion) of interleukin-6 associated with cancer
7) Confidence 0.55 Published 1996 Journal Chest Section Abstract Doc Link 8625699 Disease Relevance 0.34 Pain Relevance 0
These findings suggest that in addition to consistent improvement of exercise tolerance, cilostazol may improve lipid profiles by reducing IL-6 release.
Negative_regulation (reducing) of Localization (release) of IL-6 associated with tolerance
8) Confidence 0.51 Published 2001 Journal Atherosclerosis Section Abstract Doc Link 11583728 Disease Relevance 0.43 Pain Relevance 0.26
In addition, preoperative administration of ibuprofen has proved to reduce interleukin-6 (IL-6) release, while that of ranitidine reduced postoperative IL-6-induced C-reactive protein synthesis in patients undergoing abdominal surgery.
Negative_regulation (reduce) of Localization (release) of interleukin-6
9) Confidence 0.43 Published 2004 Journal Eur Spine J Section Abstract Doc Link 14634855 Disease Relevance 0.41 Pain Relevance 0.36
Thus, the adrenal cortex may be a potential source of IL-6, because IL-6 mRNA has been localized in the adrenal gland.
Negative_regulation (source) of Localization (localized) of IL-6 in adrenal cortex
10) Confidence 0.43 Published 2002 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11752119 Disease Relevance 0 Pain Relevance 0.89
Thus, the adrenal cortex may be a potential source of IL-6, because IL-6 mRNA has been localized in the adrenal gland.
Negative_regulation (source) of Localization (localized) of IL-6 in adrenal cortex
11) Confidence 0.43 Published 2002 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11752119 Disease Relevance 0 Pain Relevance 0.89
To rule out the possibility that DEX was inhibiting LPS-induced IL-6 release by blocking IL-6 gene expression, we tested the effect of DEX on interleukin 1beta(IL-1)-induced IL-6 release.
Negative_regulation (inhibiting) of Localization (release) of IL-6 associated with dexamethasone
12) Confidence 0.42 Published 1998 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 9784426 Disease Relevance 0.07 Pain Relevance 0.27
CONCLUSIONS: Fenoterol inhalation improved oxygenation after 270 and 360 min, attenuated the release of TNF-alpha and IL-6, and diminished the lung edema and infiltration of polymorphonuclear leukocytes.


Negative_regulation (attenuated) of Localization (release) of IL-6 in lung
13) Confidence 0.42 Published 2009 Journal Anesth. Analg. Section Body Doc Link 19535704 Disease Relevance 0 Pain Relevance 0
DEX slightly inhibited IL-1-induced IL-6 release, while IL-1 releasing action on IL-6 was significantly reduced by IND.
Negative_regulation (reduced) of Localization (releasing) of IL-6 associated with dexamethasone
14) Confidence 0.42 Published 1998 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 9784426 Disease Relevance 0.07 Pain Relevance 0.32
DEX slightly inhibited IL-1-induced IL-6 release, while IL-1 releasing action on IL-6 was significantly reduced by IND.
Negative_regulation (inhibited) of Localization (release) of IL-6 associated with dexamethasone
15) Confidence 0.42 Published 1998 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 9784426 Disease Relevance 0.07 Pain Relevance 0.32
Our data supports the hypothesis that soluble iron within AM modulates particle-core induced inflammatory responses via increased PGE2 synthesis and inhibiting IL-6 release.
Negative_regulation (inhibiting) of Localization (release) of IL-6 associated with inflammatory response
16) Confidence 0.41 Published 2009 Journal Part Fibre Toxicol Section Body Doc Link PMC2806337 Disease Relevance 0.42 Pain Relevance 0.21
Likewise, in the present study, the lack of IL-6 release was associated with higher PGE2 production by AM incubated with smaller 0.5 ?
Negative_regulation (lack) of Localization (release) of IL-6
17) Confidence 0.41 Published 2009 Journal Part Fibre Toxicol Section Body Doc Link PMC2806337 Disease Relevance 0.34 Pain Relevance 0.17
The role of PGE2 in production of IL-6 by AM is further confirmed by restoration of IL-6 release in AM with 0.5 ?
Negative_regulation (restoration) of Localization (release) of IL-6
18) Confidence 0.41 Published 2009 Journal Part Fibre Toxicol Section Body Doc Link PMC2806337 Disease Relevance 0.30 Pain Relevance 0.19
A selective EP4 receptor antagonist L-161982 was able to suppress IL-6 release, whereas an EP1 receptor antagonist, SC19220, was ineffective.
Negative_regulation (suppress) of Localization (release) of IL-6 associated with antagonist
19) Confidence 0.39 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15836625 Disease Relevance 0.24 Pain Relevance 0.57
Moreover, a protein kinase C inhibitor, calphostin C, dramatically suppressed IL-6 release, whereas a protein kinase A inhibitor H-89 and a Ca2+ chelator EGTA failed.
Negative_regulation (suppressed) of Localization (release) of IL-6 associated with kinase c inhibitor
20) Confidence 0.39 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15836625 Disease Relevance 0.13 Pain Relevance 0.44

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox